Prospective Phase I Study of Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer

Trial Profile

Prospective Phase I Study of Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Oct 2017 Planned End Date changed from 30 Jul 2018 to 31 Jan 2019.
    • 18 Oct 2017 Planned primary completion date changed from 30 Sep 2017 to 31 Mar 2018.
    • 23 Jan 2016 Trial design presented at the 2016 Gastrointestinal Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top